BioCryst Pharmaceuticals BCRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's accounts payable?
- BioCryst Pharmaceuticals (BCRX) reported accounts payable of -$60.4M in Q1 2026.
- How has BioCryst Pharmaceuticals's accounts payable changed year-over-year?
- BioCryst Pharmaceuticals's accounts payable decreased by 85.3% year-over-year, from -$32.59M to -$60.4M.
- What is the long-term trend for BioCryst Pharmaceuticals's accounts payable?
- Over 2 years (2021 to 2025), BioCryst Pharmaceuticals's accounts payable has grown at a 21.1% compound annual growth rate (CAGR), from $39.41M to $57.8M.
- What does accounts payable mean?
- Tracks the net change in obligations owed to suppliers and vendors for goods and services received. An increase indicates the company is utilizing trade credit to manage working capital, while a decrease reflects the settlement of these obligations.